Drugs / STX107
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01896843 | Jun 2013 → Jun 2016 | — | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00965432 Comparator | Sep 2009 → Feb 2010 | fragile X syndrome | Seaside Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01325740 Comparator | May 2011 → Sep 2013 | fragile X syndrome | Seaside Therapeutics, Inc. | Suspended | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STX107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01325740 ↗ |
| Action | Inhibit | “using STX107, a negative allosteric modulator at mGluR5 receptors to block the radioligand brain uptake.” NCT01896843 ↗1“Metabotropic glutamate receptor 5 negative allosteric modulator” CHEMBL3642985 ↗ |
| Modality | Small molecule | — CHEMBL3642985 ↗ |
| Route | Oral | “following single oral doses of STX107 when administered via an oral suspension” NCT00965432 ↗ |
| Target | GRM5 | “Metabotropic glutamate receptor 5 negative allosteric modulator” CHEMBL3642985 ↗ |